Onset of Tuberculosis from a Pulmonary Latent Tuberculosis Infection during Antiviral Triple Therapy for Chronic Hepatitis C.
Authors: Matsuoka S, Fujikawa H, Hasegawa H, Ochiai T, Watanabe Y, Moriyama M
Abstract
A 62-year-old man was diagnosed with the onset of tuberculosis (Tb) from a pulmonary latent tuberculosis infection (LTBI) during triple therapy with pegylated interferon α2a, ribavirin, and telaprevir for a chronic hepatitis C infection in 2013 before interferon (IFN)-free anti-viral therapy was introduced in Japan. A liver biopsy before IFN treatment revealed the presence of epithelioid cell granulomas (ECGs). IFN may also be employed for chronic hepatitis B infection and malignant tumors, thus, special attention must ...
Source: Internal Medicine - August 3, 2016 Category: Internal Medicine Tags: Intern Med Source Type: research
Chronic hepatitis C patients prior to broad access to interferon-free treatments in Germany.
Abstract
In 2014, the first interferon-free treatment options for chronic Hepatitis C (CHC) became available in Europe introducing a new era of highly effective and well tolerated oral treatment options for CHC. The data from the cross-sectional study CURRENT-C highlights the epidemiological characteristics of patients with CHC in Germany. During the period that the study was conducted, the approval of the combination drugs for the treatment of CHC was imminent.Between June and November 2014, 1471 CHC-patients not receiving anti-HCV treatment were included nationwide in 40 German centers specializing in vi...
Source: Zeitschrift fur Gastroenterologie - July 31, 2016 Category: Gastroenterology Authors: Hüppe D, Buggisch P, Christensen S, Heiken H, Mauss S, Naumann U, Fischer C, Kleine H, Huelsenbeck J Tags: Z Gastroenterol Source Type: research
Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy
Objectives: Ribavirin (RBV) induced anemia may be influenced by host genetic factors affecting RBV transport solute carrier (SLC) or metabolism inosine triphosphatase (ITPA), as already reported. We investigated the influence of single nucleotide polymorphisms (SNPs) on SLC genes on anemia, RBV trough concentration (Ctrough) and response in HIV–hepatitis C virus coinfected patients receiving triple therapy with boceprevir or telaprevir.
Methods: Patients from the ANRS HC26/HC27 studies were genotyped for SLC28A3 SNPs (rs10868138 and rs56350726) and SL29A1 SNPs (rs760370). Hemoglobin (Hb) decline was collected at baselin...
Source: AIDS - July 29, 2016 Category: Infectious Diseases Tags: Clinical Science: Concise Communication Source Type: research
Optimisation of triple therapy for patients with chronic hepatitis C: a systematic review
ConclusionsThe present study shows how improved results of triple therapy are mainly observed in some patients’ subsets and are accompanied by increased risk of AEs compared to dual therapy. These results might be useful for optimising treatment of chronic hepatitis C when IFN‐free regimens are unavailable. (Source: European Journal of Clinical Investigation)
Source: European Journal of Clinical Investigation - July 26, 2016 Category: Journals (General) Authors: Valentina Pecoraro, Elisabetta Cariani, Erica Villa, Tommaso Trenti Tags: Review Source Type: research
Optimization of triple therapy for patients with chronic hepatitis C: a systematic review
This article is protected by copyright. All rights reserved. (Source: European Journal of Clinical Investigation)
Source: European Journal of Clinical Investigation - July 3, 2016 Category: Journals (General) Authors: Valentina Pecoraro, Elisabetta Cariani, Erica Villa, Tommaso Trenti Tags: Review Source Type: research
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
CONCLUSIONS The most common nursing problems in the care of the patient were associated with the diagnostic process, therapies used (including experimental treatment), and progressive liver failure. The therapeutic success should be attributed to the intensive supervision and monitoring of viremia, immediate inclusion of adequate treatment methods, adequate patient preparation for diagnostic tests, and careful care after diagnostics, as well as psychological support and education.
PMID: 27357745 [PubMed - in process] (Source: Annals of Transplantation)
Source: Annals of Transplantation - July 2, 2016 Category: Transplant Surgery Authors: Hreńczuk M, Sowińska R, Tronina O, Małkowski P, Durlik M, Pacholczyk M, Kosieradzki M Tags: Ann Transplant Source Type: research
Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014.
CONCLUSIONS: At the end of 2014, patients were almost exclusively using new therapies, which was associated with increased treatment rate, especially among patients who may need urgent treatment but are intolerant or ineligible for interferon-based regimens.
PMID: 27355910 [PubMed - in process] (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - July 1, 2016 Category: Health Management Authors: Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA Tags: Am J Manag Care Source Type: research
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors.
Authors: Miotto N, Mendes LC, Zanaga LP, Goncales ES, Lazarini MS, Pedro MN, Goncales FL, Stucchi RS, Vigani AG
Abstract
The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized qu...
Source: Brazilian Journal of Medical and Biological Research - June 30, 2016 Category: Research Tags: Braz J Med Biol Res Source Type: research
Viruses, Vol. 8, Pages 176: Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance
While addition of the first-approved protease inhibitors (PIs), telaprevir and boceprevir, to pegylated interferon (PEG-IFN) and ribavirin (RBV) combination therapy significantly increased sustained virologic response (SVR) rates, PI-based triple therapy for the treatment of chronic hepatitis C virus (HCV) infection was prone to the emergence of resistant viral variants. Meanwhile, multiple direct acting antiviral agents (DAAs) targeting either the HCV NS3/4A protease, NS5A or NS5B polymerase have been approved and these have varying potencies and distinct propensities to provoke resistance. The pre-clinical in vivo assess...
Source: Viruses - June 21, 2016 Category: Virology Authors: Ahmed MesalamKoen VercauterenPhilip Meuleman Tags: Review Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon)
Source: Journal of Interferon - June 20, 2016 Category: Research Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon and Cytokine Research)
Source: Journal of Interferon and Cytokine Research - June 20, 2016 Category: Molecular Biology Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Peginterferon-α-2a/ribavirin/telaprevir
(Source: Reactions Weekly)
Source: Reactions Weekly - May 31, 2016 Category: Drugs & Pharmacology Source Type: research
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
CONCLUSION: Telaprevir-based triple therapy in patients with recurrent genotype 1 HCV infection following liver transplantation produced high rates of SVR. Therapeutic concentrations of immunosuppressants were maintained successfully through dose modification during telaprevir treatment.
PMID: 27236150 [PubMed - as supplied by publisher] (Source: Annals of Hepatology)
Source: Annals of Hepatology - May 29, 2016 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Plumbagin, a Plant ‐Derived Compound, Exhibits Antifungal Combinatory Effect with Amphotericin B against Candida albicans Clinical Isolates and Anti‐hepatitis C Virus Activity
In this study, plumbagin has been evaluated in vitro for its antifungal combinatory effect with amphotericin B against Candida albicans (C. albicans) clinical isolates and anti‐hepatitis C virus (HCV) activity. Antifungal activity was determined by broth microdilution method, and combinatory effect was evaluated by checkerboard assay according to ΣFIC indices, while cytotoxicity was determined by MTT assay. Anti‐HCV activity was determined in infected Huh7.5 cells using quantitative real‐time reverse transcription PCR, and cytotoxicity was evaluated by MTT assay. Plumbagin exerted inhibitory effect against all C. al...
Source: Phytotherapy Research - May 23, 2016 Category: Biochemistry Authors: Sherif T. S. Hassan, Kate řina Berchová‐Bímová, Jan Petráš Tags: Research Article Source Type: research
Plumbagin, a Plant‐Derived Compound, Exhibits Antifungal Combinatory Effect with Amphotericin B against Candida albicans Clinical Isolates and Anti‐hepatitis C Virus Activity
In this study, plumbagin has been evaluated in vitro for its antifungal combinatory effect with amphotericin B against Candida albicans (C. albicans) clinical isolates and anti‐hepatitis C virus (HCV) activity. Antifungal activity was determined by broth microdilution method, and combinatory effect was evaluated by checkerboard assay according to ΣFIC indices, while cytotoxicity was determined by MTT assay. Anti‐HCV activity was determined in infected Huh7.5 cells using quantitative real‐time reverse transcription PCR, and cytotoxicity was evaluated by MTT assay. Plumbagin exerted inhibitory effect against all C. al...
Source: Phytotherapy Research - May 23, 2016 Category: Biochemistry Authors: Sherif T. S. Hassan, Kateřina Berchová‐Bímová, Jan Petráš Tags: Research Article Source Type: research
